Effect of Tirofiban on Prognosis of Patients with Acute Large Vessel Occlusion Stroke Treated with IVT Bridging EVT

CHEN Jing; CHEN Zepeng; JIANG Pei; ZHANG Qiang; ZHOU Jinghua; ZHOU Huajun

doi:10.14033/j.cnki.cfmr.2024.18.001

Abstract：Objective:To observe the effect of Tirofiban on the prognosis of patients with acute large vessel occlusion stroke(ALVOS)treated with intravenous thrombolysis(IVT)bridging endovascular therapy(EVT).Method:A total of 73 patients with ALVOS who admitted to Yidu People's Hospital from January 2021 to January 2023 were selected as the research objects,the patients were divided into the control group(36 cases)and the study group(37 cases)according to the random number table method.The control group was treated with IVT bridging EVT,and the study group was treated with Tirofiban on this basis,the number of thrombectomy and vascular recanalization rate,National Institutes of Health stroke scale(NIHSS)score,modified Rankin scale(mRS)score,neurological serological indicators[nerve growth factor(NGF),brain-derived neurotrophic factor(BDNF),central nervous system specific protein β(S100β)],coagulation function[prothrombin time(PT),activated partial thromboplastin time(APTT),D-dimer(D-D)]and safety were compared between two groups.Result:The number of thrombectomy in the study group was less than that in the control group,and the difference was statistically significant(P<0.05);there was no significant difference in the vascular recanalization rate between two groups(P>0.05).The NIHSS score,mRS score,S100β and D-D levels in the study group after treatment were lower than those in the control group,NGF and BDNF levels were higher than those in the control group,PT and APTT were longer than those in the control group,and the differences were statistically significant(P<0.05).There were no significant differences in the symptomatic intracranial hemorrhage rate,various types of bleeding rate,recurrence rate and mortality between two groups(P>0.05).Conclusion:The addition of Tirofiban during IVT bridging EVT treatment can improve the neurological and coagulation function levels of ALVOS patients,with a good short-term prognosis.